Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 May;2(2):127-132.
doi: 10.2217/mmt.15.9. Epub 2015 May 18.

Electrochemotherapy in melanoma patients: a single institution experience

Corrado Caracò  1   1 , Ugo Marone  1   1 , Ester Simeone  1   1 , Antonio Maria Grimaldi  1   1 , Gerardo Botti  2   2 , Maurizio Del Giudice  3   3 , Paolo Antonio Ascierto  1   1 , Nicola Mozzillo  1   1
Affiliations

Electrochemotherapy in melanoma patients: a single institution experience

Corrado Caracò et al. Melanoma Manag. 2015 May.

Abstract

Aim: This study was undertaken to update the outcome of the treated lesions with electrochemotherapy (ECT) plus intravenous injection of bleomycin in patients with in-transit disease or distant cutaneous metastases in melanoma patients.

Patients & methods: 89 patients with relapsed and refractory cutaneous melanoma metastases or in-transit disease were submitted to 126 treatments of ECT.

Results: 34 patients (38.2%) had a partial response and 43 had a complete response (48.3%). 12 patients (13.5%) had no change or progressive disease. The objective response rate was 67.5%.

Conclusion: The favorable outcome obtained in the present study demonstrates that ECT is a reliable, easy, fast and effective procedure showing benefits in terms of curative and palliative treatment for unresectable cutaneous lesions respecting the quality of life.

Keywords: cutaneous metastases; electrochemotherapy; in-transit; loco-regional treatments; melanoma.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.

Figures

<b>Figure 1.</b>
Figure 1.. Treatment response.
See this image and copyright information in PMC

References

    1. GLOBOCAN 2012. Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr/Default.aspx
    1. Robinson JK, Baker MK, Hillhouse JJ. New approaches to melanoma prevention. Dermatol. Clin. 2012;30:405–412. - PMC - PubMed
    1. Kretschmer L, Beckmann I, Thoms KM, Mitteldorf C, Bertsch HP, Neumann C. Factors predicting the risk of in-transit recurrence after sentinel lymphonodectomy in patients with cutaneous malignant melanoma. Ann. Surg. Oncol. 2006;13:1105–1112. - PubMed
    1. Gehl J. Electrochemotherapy: theory and methods, perspectives for drug delivery gene therapy and research. Acta Physiol. Scand. 2003;177(4):437–447. - PubMed
    1. Sersa G, Miklavčič D, Cemazar M, Rudolf Z, Pucihar G, Snoj M. Electrochemotherapy in treatment of tumors. Eur. J. Surg. Oncol. 2007;34:232–240. - PubMed

LinkOut - more resources